These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intratumoral administration of the immunologic adjuvant AS01 Tijtgat J; Geeraerts X; Boisson A; Stevens L; Vounckx M; Dirven I; Schwarze JK; Raeymaeckers S; Forsyth R; Van Riet I; Tuyaerts S; Willard-Gallo K; Neyns B J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212127 [TBL] [Abstract][Full Text] [Related]
4. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1) Vounckx M; Tijtgat J; Stevens L; Dirven I; Ilsen B; Vandenbroucke F; Raeymaeckers S; Vekens K; Forsyth R; Geeraerts X; Van Riet I; Schwarze JK; Tuyaerts S; Decoster L; De Ridder M; Dufait I; Neyns B Cancer Immunol Immunother; 2024 Jul; 73(9):167. PubMed ID: 38954010 [TBL] [Abstract][Full Text] [Related]
5. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Tijtgat J; De Munck J; Dufait I; Schwarze JK; Van Riet I; Franceschini L; Breckpot K; Aerts JL; Neyns B; Tuyaerts S Front Immunol; 2021; 12():733506. PubMed ID: 34777344 [TBL] [Abstract][Full Text] [Related]
6. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1 Kalus P; De Munck J; Vanbellingen S; Carreer L; Laeremans T; Broos K; Dufait I; Schwarze JK; Van Riet I; Neyns B; Breckpot K; Aerts JL Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563257 [TBL] [Abstract][Full Text] [Related]
10. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745 [TBL] [Abstract][Full Text] [Related]
11. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831 [TBL] [Abstract][Full Text] [Related]
12. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
13. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575 [TBL] [Abstract][Full Text] [Related]
14. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J Front Oncol; 2020; 10():611. PubMed ID: 32457834 [No Abstract] [Full Text] [Related]
15. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812 [TBL] [Abstract][Full Text] [Related]
19. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]